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Abstract
Background: Using cardiovascular magnetic resonance imaging (CMR), it is possible to detect diffuse fibrosis of the
left ventricle (LV) in patients with atrial fibrillation (AF), which may be independently associated with recurrence of
AF after ablation. By conducting CMR, clinical, electrophysiology and biomarker assessment we planned to investigate
LV myocardial fibrosis in patients undergoing AF ablation.
Methods: LV fibrosis was assessed by T1 mapping in 31 patients undergoing percutaneous ablation for AF. Galectin-3,
coronary sinus type I collagen C terminal telopeptide (ICTP), and type III procollagen N terminal peptide were measured
with ELISA. Comparison was made between groups above and below the median for LV extracellular volume fraction
(ECV), followed by regression analysis.
Results: On linear regression analysis LV ECV had significant associations with invasive left atrial pressure (Beta 0.49, P =
0.008) and coronary sinus ICTP (Beta 0.75, P < 0.001), which remained significant on multivariable regression.
Conclusion: LV fibrosis in patients with AF is associated with left atrial pressure and invasively measured levels of ICTP
turnover biomarker.
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Background
Percutaneous pulmonary vein (PV) isolation is often used
for rhythm control in patients with atrial fibrillation (AF).
However, at least one third of such patients experience a re-
currence of AF even after multiple procedures [1]. This is
most commonly due to reconnection of the pulmonary
veins, however in a significant proportion of patients this is
not the case and the mechanism(s) in these instances is un-
clear. Identification of AF patients who are likely to maintain
sinus rhythm after the procedure is important, to reduce un-
necessary exposure to procedural risks and expense.
Fibrosis is a hallmark of the left atrial (LA) pathological
changes associated with AF development and recurrence
after ablation, and research has explored the clinical utility
of LA fibrosis assessment by various methods [2–6].
However, left ventricular (LV) fibrosis is also more
prominent in AF patients than those without AF, and may
be a predictor of AF recurrence [7, 8]. Diffuse LV fibrosis
can be estimated using cardiovascular magnetic resonance
(CMR), by calculating the extracellular volume fraction
(ECV) from native and post contrast T1 mapping [9].
Circulating biomarkers such as type I collagen C terminal
telopeptide (ICTP), type III procollagen N terminal peptide
(PIIINP) and galectin 3 (gal-3) are markers of fibrosis that
can be measured in the bloodstream [2]. They offer minim-
ally invasive assessment of fibrosis, and would be a useful
tool for improving patient selection if their clinical utility in
doing so could be confirmed. They may also have a re-
search application, in defining the mechanism of AF.
Although LV fibrosis has been associated to some
extent with AF and AF recurrence after treatment, the
mechanism behind this association is not clear. Raised
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LA pressure has been associated with recurrence of AF
after catheter ablation, however the relationship between
LA pressure and ventricular cardiac fibrosis in AF pa-
tients has not been studied in depth [10]. LA pressure is
a routinely available direct measurement during AF pro-
cedures after trans-septal puncture, and further study
may provide mechanistic insights into any haemo-
dynamic influence on LV fibrosis in this patient group.
We investigated the interaction between LV fibrosis, LA
fibrosis, and LA pressure, all of which have been associ-
ated with arrhythmia recurrence in patients after AF abla-
tion. This interaction was examined in a multi-modality
fashion, using CMR, invasive LA voltage mapping, LA
pressure measurement and circulating biomarker assays.
We hypothesized that LA fibrosis, measured by voltage
mapping, is associated with diffuse LV fibrosis, measured
by T1 mapping, and that raised LA pressure is associated
with both of these measures. To attempt to gain a mech-
anistic insight into the pathological process of the fibrosis
identified via these imaging methods, we also tested levels
of circulating fibrosis biomarkers, including from intracar-
diac blood.
Methods
Ethical approval was granted by the UK National Re-
search Ethics Service Committee - Leeds West (ref. 13/
YH/0349). Thirty-one patients undergoing first-time LA
ablation for paroxysmal, persistent, or long-standing-
persistent AF were recruited at the Leeds General In-
firmary between September 2014 and August 2015, as
part of a wider study consecutive cohort (n = 93) under-
going biomarker assessment before ablation. Details of
the wider cohort have been published [6, 11]. Of this co-
hort, 31 participants was the maximum number that
could be recruited to the CMR study presented in this
article. Patients with systemic inflammatory disease, re-
cent or active malignancy, severe kidney disease (esti-
mated glomerular filtration rate (eGFR) < 30ml/min/
1.73m2) connective tissue disease, or any contra-
indication to CMR were excluded. Written informed
consent was gained from all participants.
CMR scans were carried out on a dedicated 1.5 Tesla
CMR scanner (Ingenia, Philips Healthcare, Best,
Netherlands). Venepuncture was performed immediately
prior to the scan, and blood was inserted into potassium
EDTA tubes for on-site analysis of haematocrit on a
ADVIA 2120 analyser (Siemens Healthineers, Erlangen,
Germany). Cine imaging in multiple planes was per-
formed, to allow measurement of standard LA and LV
dimensions. Native T1 maps were acquired (electrocar-
diogram (ECG) triggered 5 s(3 s)3 s Modified Look
Locker Inversion Recovery (MOLLI) scheme, recon-
structed voxel size 1.2 × 1.2x10mm3) on a mid-
ventricular short axis slice. Fifteen minutes after
administration of 0.15 mmol/kg intravenous gadolinium
based contrast agent a post-contrast T1 map was ac-
quired with identical planning (4 s(2 s)3 s(2 s)2 s
MOLLI). ECV was calculated from the pre and post con-
trast T1 maps [9].
Radiofrequency (RF) ablation was performed according
to the 2012 international consensus statement [12]. Under
conscious sedation or local anaesthetic, venous access was
obtained via the right and left femoral veins. After trans-
septal puncture, LA bipolar voltages were recorded using
a high-density circular electrophysiological (EP) mapping
catheter and 3D mapping system (Lasso/CARTO 3,
Biosense-Webster or Optima/Ensite Velocity, St. Jude
Medical, St. Paul, Minnesota, USA). Mean LA pressures
were recorded by transducing the LA sheath. Blood was
aspirated from the femoral vein, right atrium, LA, and cor-
onary sinus ostium for later analysis. RF energy was then
applied to the PV antra according to standard techniques
to perform wide-area circumferential ablation in order to
achieve PV isolation. In non-paroxysmal AF, linear abla-
tion or substrate – targeted ablation (e.g. of complex frac-
tionated electrograms) were carried out at the operator’s
discretion. Successful PV isolation was confirmed in all
patients by demonstration of exit and entry block.
Raw EP mapping data were exported from the system
according to the manufacturer’s instructions, and re-
formatted to allow 3D geometry and voltage maps to be
re-created in analysis software (Paraview). This allowed
voltage values to be digitally analysed according to previ-
ously published methods [13]; The PV, LA appendage
and mitral valve were excluded from analysis. Bipolar
voltage of less than 0.5 mV was considered to represent
fibrosis, and this was expressed as a percentage of the
overall LA endocardial area, excluding the PVs, mitral
valve and LA appendage.
Intra-cardiac and peripheral blood aspirated during
ablation procedures was analysed using commercially
available enzyme-linked immunosorbent assay (ELISA)
kits: PIIINP (Elabscience, Beijing, China), gal-3
(Elabscience, Beijing, China) and ICTP (Cusabio Life Sci-
ence, Wuhan, China). Further details of the ELISA ana-
lysis have been previously published [11]. ICTP levels
were analysed from coronary sinus blood, gal-3 and
PIIINP levels were analysed as a mean of peripheral and
intra-cardiac levels, based on the findings of this previ-
ous work [11].
All patients were followed up for 365 days according to
standard care, with investigation of possible recurrence
based on symptoms. In patients without symptoms or doc-
umented arrhythmia recurrence after this 365-day period,
24-h electrocardiogram (ECG) monitoring was performed.
Arrhythmia recurrence was defined as any documented AF
or atrial arrhythmia lasting more than 30 s, occurring more
than 60 days after ablation.
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Statistical analysis
Normally distributed data are expressed as mean ±
standard deviation. Non-parametric data are expressed
as median (interquartile range). Categorical data are
expressed as frequency (percentage). Data were assessed
for normality using the Shapiro-Wilk test and non-
parametric data were log-transformed prior to analysis if
possible. For comparison, we separated patients into two
groups with above and below median LV ECV values.
Differences in characteristics between these groups were
then assessed using independent-sample t-tests for con-
tinuous variables or chi-squared tests for categorical var-
iables. Where transformation of non-parametric data
was not possible, Mann-Whitney U test was performed
to compare distributions. Univariate linear regression
analysis was performed to examine relationships be-
tween LV ECV and baseline characteristics. For the mul-
tivariable analysis, the forced-entry model was used to
identify predictors. Analysis was carried out using SPSS
(version 22, Statistical Package for the Social Sciences
(SSPS), International Business Machines, Inc., Armonk,
New York, USA). A 2-sided P-value of < 0.05 was con-
sidered to indicate statistical significance.
Results
Patient characteristics
All 31 recruited had CMR assessment. The participants
were typical of AF ablation patients and had few comor-
bidities apart from hypertension (Table 1). Mean LA vol-
ume of the cohort was elevated. All patients had LV
ejection fraction (LVEF) more than 45%. The majority
(80.6%) had paroxysmal AF (PAF), and the remainder
had either persistent or long-standing persistent AF,
grouped together for analysis as ‘non-PAF’.
Analysis
Table 2 shows the results of the comparisons between the
cohort when split above and below the median LV ECV
value of 23.9%. The above-median LV ECV group had
higher mean LA pressure (13 ± 6mmHg vs. 8 ± 4mmHg,
p = 0.010) and higher ICTP levels (451 (154) ng/ml vs. 212
(146) ng/ml, p = 0.001) (Fig. 1). These differences
remained significant after multivariable analysis (LAP β =
0.791, p < 0.001 and ICTP β = 0.592, p = 0.001) (Table 3).
The above-median ECV group had a longer duration of
AF (52.0 (51.5) months vs 48.8 (57.9) months, p = 0.038),
but this was not significant on regression analysis. There
was no difference in LA low voltage area between the
above and below median ECV groups (22 ± 7% vs 17 ± 7%,
respectively, 95% CI − 1.06 to 10.9% p = 0.102). No other
differences regarding CMR assessment were identified, in-
cluding the other biomarkers.
In addition to LV ECV, analysis of native T1 mapping
values was performed. An association between with ICTP
levels was found on univariable analysis (beta = 0.46, p =
0.026). Mean LA pressure also approached significance
(beta = 0.348, p = 0.070). After multivariable analysis, the
association with ICTP remained significant (beta =
0.44, p = 0.043) but the association with mean LA
pressure did not.
Discussion
Associations with CMR T1 mapping parameters
Recent studies have demonstrated that T1 mapping dur-
ing AF is not only feasible but can give important clin-
ical information [14, 15]. In this study, the presence of
AF during the scan appeared to have no effect on the
ECV values.
Table 1 Participant characteristics
Characteristic Distribution
Age (years) 56.7 ± 12.7
BMI (kg/m2) 27.5 (5.9)
Sex
Female 9 (29.0)
Male 22 (71.0)
AF classification
Paroxysmal 25 (80.6)
Non-paroxysmal 6 (19.4)
Time since AF diagnosis (months) 51.3 (53.9)
In AF during CMR scan 9 (29.0)
Diabetes mellitus 1 (3.2)
Ischaemic heart disease 2 (6.5)
Hypertension 9 (29.0)
Systolic blood pressure (mmHg) 125 ± 23
Diastolic Blood pressure (mmHg) 78 ± 15
LA Volume (ml) 102 ± 40
minimum 47.5, maximum 195.4
LV end-diastolic volume (ml) 158 ± 37
LV stroke volume (ml) 93 ± 24
Cardiac output (L/min) 6.3 ± 1.6
LV ejection fraction (%) 59.2 ± 7.1
LV Mass (g) 87.3 ± 24.7
Native T1 (ms) 985 ± 35.5
LV ECV (%) 24.1 ± 2.5
Mean LA pressure (mmHg) 9.0 (5.0)
LA low voltage area (%) 20.5 ± 7.1
ICTP (ng/ml) 317.1 ± 190.1
Gal-3 (ng/ml) 36.4 ± 32.9
PIIINP (pg/ml) 76.4 ± 46.4
AF Atrial fibrillation, BMI Body mass index, ECV Extracellular volume fraction,
gal-3 Galectin 3, ICTP Type I collagen C terminal peptide, LA Left atrial, LV Left
ventricular, LVEF Left ventricular ejection fraction, PIIINP Type III procollagen N
terminal peptide
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Table 2 LV ECV comparison
LV ECV
Above median LV ECV Below median LV ECV P Value
ICTP ng/ml 451 (154) 212 (146) 0.001
Gal-3 ng/ml 29.2 (19.4) 43.5 (41.8) 0.241
PIIINP pg/ml 63.4 (50.4) 87.2 (58.0) 0.413
LA voltage (% < 0.5 mV) 22.3 ± 7.0 17.4 ± 6.6 0.102
Mean LA pressure (mmHg) 13 ± 6 8 ± 4 0.010
Age (years) 56.5 ± 13.0 56.9 ± 12.9 0.918
Time since AF diagnosis (months) 52.0 (31.5) 48.8 (57.9) 0.038
BMI (kg/m2) 27.4 ± 4.3 29.3 ± 6.0 0.316
LA vol/BSA (ml/m2) 46.6 (21.5) 42.9 (15.9) 0.740
LV EDV/BSA (ml/m2) 71.4 ± 14.4 79.3 ± 14.9 0.150
LV ejection fraction (%) 61 ± 8 57 ± 6 0.140
LV Mass/BSA (g/m2) 43.3 (8.7) 39.1 (10.1) 0.522
Systolic blood pressure (mmHg) 122.8 ± 21.3 127.4 ± 25.8 0.590
Diastolic blood pressure (mmHg) 78.9 ± 12.1 76.3 ± 17.0 0.616
PAF 13 (86.7) 12 (80.0) 0.930
Male 10 (66.7) 12 (80.0) 0.283
Sinus rhythm during scan 11 (73.3) 11 (73.3) 1.00
Recurrence of AF 8 (53.3) 7 (46.7) 0.715
The median value for LV ECV is 24.0%. Values are ‘mean ± standard deviation’, ‘median (interquartile range)’ or ‘frequency (%)’. P values represent results of
Student’s t-test for normally distributed data, Mann-Whitney U test for non-parametric data, and chi-squared test for categorical data. Statistically significant
results highlighted in bold. BSA Body surface area, EDV End-diastolic volume, PAF Paroxysmal atrial fibrillation
Fig. 1 Scatterplots of associations between type I collagen C terminal telopeptide (ICTP)/left ventricular (LV) extracellular volume fraction (ECV)
and left atrial (LA) pressure/LV ECV
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We have shown that mean LA pressure is associated with
LV ECV in AF patients, to our knowledge a novel finding.
LV fibrosis appears to be more pronounced in AF pa-
tients than in non-AF controls [16]. A potential mechanis-
tic explanation for this is that LV end-diastolic pressure is
elevated in the presence of increased ventricular stiffness
and diastolic dysfunction, and this in turn causes an in-
crease in LA pressure, dimension and altered function as a
result of the increased atrial workload during ventricular
diastole [17]. In their analysis of over 400 patients, Park
et al showed that elevated LA pressure is associated with
both electro-anatomical remodelling of the LA, and AF re-
currence after ablation [10]. It therefore follows that an in-
crease in LV ECV may be related to an increase in LA
pressure as seen in our study, and, speculatively, incidence
and prognosis of AF.
An association between increasing duration of AF and
ECV, and in keeping with this, between persistent AF
and increased ECV, would be expected based on previ-
ous research [7]. Although there was a higher duration
of AF in the above-median ECV group, this association
was not shown to be significant after regression analysis.
An explanation for this may be that the study by Neilan
et. al, [7], demonstrating the predictive value of LV ECV
for AF recurrence, was much larger (n = 145) and better
powered to detect subtle associations.
Most LV ECV values recorded in this study were
within the normal range; indeed, in comparison with
data published from our centre, ECV is equivalent to
sedentary healthy controls and lower than ECV derived
from cohorts with established myocardial pathology
[18–20]. This is likely to be due to the patient group se-
lected for this study; those patients undergoing AF abla-
tion are generally at an early point in the development
of their AF, predominantly in paroxysmal rather than
persistent or long-standing persistent AF, and have little
or no clinically relevant underlying structural heart ab-
normality. This technique may be able to identify at an
early stage in the disease process those patients with a
lower chance of rhythm control success when AF has
been diagnosed. At least one previous study has sug-
gested this, and further research is required to explore
this concept further [7].
The other association with LV ECV and native T1 de-
scribed in this study is with ICTP levels. To our know-
ledge, this is a novel finding in both instances. ICTP is a
product of the catabolism of type 1 collagen, the most
abundant form collagen in the myocardium. Studies
examining its predictive value in AF ablation are sparse
and heterogeneous, but there has been some suggestion
that it predicts AF recurrence after rhythm control inter-
vention [21, 22]. In previous work we have shown that
coronary sinus ICTP levels are higher than intra-atrial
levels in this AF patient cohort, suggesting that the pre-
dominant site of increased type-I collagen turnover is the
ventricle [11]. This should be considered when interpret-
ing studies which have examined circulating ICTP levels
in the context of AF – the association between ICTP and
AF may represent ventricular pathology, not atrial [11, 23,
24]. This association may warrant further study, particu-
larly to ascertain any clinical benefit of using this
biomarker in AF recurrence risk stratification, or the iden-
tification of patients who may benefit from more extensive
LA ablation than pulmonary vein isolation.
Association with LA low voltage
LA voltage mapping data was used as a surrogate marker
of LA fibrosis. Although there was more LA low-voltage
area in the above-median ECV group, this difference was
not significant. Other studies have found low voltage tis-
sue in the LA to be an independent predictor of AF recur-
rence [5, 6]. The reason for this discrepancy is not clear,
but may be related to the small sample size of this study.
Limitations
A main limitation of this study is the small number of
participants. Nevertheless, the study population is repre-
sentative of AF ablation patients in general and the mul-
tiple modality assessment of fibrosis, coupled with the
Table 3 Regression analysis
Characteristic Association with ECV
Beta P Value
Age (years) −0.172 0.354
Time since AF diagnosis (months) 0.038 0.849
BMI (kg/m2) −0.267 0.146
Female sex 0.296 0.106
Non - PAF 0.116 0.535
Hypertension 0.103 0.582
CHA2DS2VASc 0.008 0.964
LA vol (ml) −0.247 0.181
LV EDV (ml) −0.294 0.115
LV ejection fraction (%) 0.184 0.330
LV Mass (g) −0.250 0.183
Systolic blood pressure (mmHg) 0.033 0.859
Diastolic blood pressure (mmHg) 0.069 0.714
Mean LA pressure (mmHg) 0.486
0.791
0.008
< 0.001
% LA voltage (< 0.5 mV) 0.257 0.225
ICTP 0.754
0.592
< 0.001
0.001
PIIINP −0.004 0.989
Gal-3 − 0.142 0.454
Results in italics represent multivariable analysis results. Results in bold
represent statistically significant associations after multivariable analysis
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measurement of LA pressure, is unique and has pro-
vided novel insights.
A clearly defined value for ‘fibrotic’ tissue based on
histological validation was not used, however the results
(particularly the association between ICTP and LV ECV)
do imply such a relationship exists. In this study, there
was no control group with which to compare ECV
values. It should be noted that isolated measurement of
LA pressure during an ablation procedure may not re-
flect chronic load status, however repeated or continu-
ous direct LA pressure monitoring is not feasible and
the size of this potential error is unknown.
Conclusion
Higher LV ECV in AF patients is associated with higher
LA pressure and type 1 collagen turnover.
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